Education
About Us
Working with TipRanks
Follow Us
Vaxart (VXRT)
:VXRT
VXRT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.26 - $1.07
Previous CloseN/A
Volume1.40M
Average Volume (3M)3.19M
Market Cap
$84.24M
Enterprise Value$71.39M
Total Cash (Recent Filing)$41.94M
Total Debt (Recent Filing)$16.83M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Aug 13, 2025EPS Estimate
-0.09Last Dividend Ex-Date
Nov 09, 2012Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding228,913,670
10 Day Avg. Volume802,645
30 Day Avg. Volume3,191,506
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue1.51
Enterprise Value/Gross Profit1.51
Enterprise Value/Ebitda-1.56
Forecast
1Y Price Target
$6.00Price Target Upside1521.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase II COVID-19 vaccine trial is progressing rapidly, with the sentinel cohort enrollment ahead of schedule, indicating strong advancement in the study.
Growth PotentialVaxart's efforts to refine its norovirus program address a significant unmet need in a market with no approved vaccines, showcasing potential for growth and innovation.
Regulatory MilestonesVXRT's norovirus oral vaccine unique competitive position to further benefit from upcoming regulatory milestones.
Vaccine DevelopmentVaxart advances with $453M BARDA-backed COVID-19 vaccine, poised to lead in mucosal immunity.
Bears Say
Investor PerceptionInvestor perception of the norovirus opportunity has considerable room for improvement given the significant disease burden and the lack of approved or late-stage programs.
Vaxart News
VXRT FAQ
What was Vaxart’s price range in the past 12 months?
Vaxart lowest stock price was $0.26 and its highest was $1.07 in the past 12 months.
What is Vaxart’s market cap?
Vaxart’s market cap is $84.24M.
When is Vaxart’s upcoming earnings report date?
Vaxart’s upcoming earnings report date is Aug 13, 2025 which is in 5 days.
How were Vaxart’s earnings last quarter?
Vaxart released its earnings results on May 13, 2025. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.097 by $0.027.
Is Vaxart overvalued?
According to Wall Street analysts Vaxart’s price is currently Undervalued.
Does Vaxart pay dividends?
Vaxart pays a Notavailable dividend of $12.188 which represents an annual dividend yield of N/A. See more information on Vaxart dividends here
What is Vaxart’s EPS estimate?
Vaxart’s EPS estimate is -0.09.
How many shares outstanding does Vaxart have?
Vaxart has 228,913,670 shares outstanding.
What happened to Vaxart’s price movement after its last earnings report?
Vaxart reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.097. Following the earnings report the stock price went down -4.762%.
Which hedge fund is a major shareholder of Vaxart?
Currently, no hedge funds are holding shares in VXRT
Vaxart Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (1521.62% Upside)
$6.00 (1521.62% Upside)
Hedge Fund Trend
Increased
By 36.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $53.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 9.6%
Last 30 Days ▼ 9.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.10%
12-Months-Change
Fundamentals
Return on Equity
-114.74%
Trailing 12-Months
Asset Growth
78.82%
Trailing 12-Months
Company Description
Vaxart
Vaxart, Inc. is a clinical-stage biotechnology company focused on developing oral recombinant vaccines based on its proprietary oral vaccine platform. The company is headquartered in South San Francisco, California, and operates primarily within the biotechnology and pharmaceutical sectors. Vaxart's core products involve the development of vaccines administered orally in tablet form, targeting infectious diseases such as COVID-19, influenza, norovirus, and respiratory syncytial virus (RSV).
VXRT Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented several positive developments, including significant revenue growth, progress in clinical trials, and promising preclinical results. However, these were balanced by challenges such as workforce reductions, CFO resignation, and the risk of NASDAQ delisting. The sentiment is balanced by both achievements and significant challenges.View all VXRT earnings summariesVXRT Stock 12 Month Forecast
Average Price Target
$6.00
▲(1521.62% Upside)
Technical Analysis
MacroGenics
―
Immunic
―
Zentalis Pharmaceuticals
―
Orchestra BioMed Holdings
―
Sagimet Biosciences, Inc. Class A
―
Ownership Overview
1.87% Insiders
5.47% Mutual Funds
0.03% Other Institutional Investors
88.00% Public Companies and
Individual Investors